肠道营养不良与阿尔茨海默病淀粉样变性相关性的深入研究

IF 0.4 Q4 PHARMACOLOGY & PHARMACY Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2022-12-01 DOI:10.1177/0976500X221150310
S. Kondaveeti, Dithu Thekkekkara, Lakshmi Narayanan T, S. Manjula, Y. M. Tausif, Amrita Babu, S. Meheronnisha
{"title":"肠道营养不良与阿尔茨海默病淀粉样变性相关性的深入研究","authors":"S. Kondaveeti, Dithu Thekkekkara, Lakshmi Narayanan T, S. Manjula, Y. M. Tausif, Amrita Babu, S. Meheronnisha","doi":"10.1177/0976500X221150310","DOIUrl":null,"url":null,"abstract":"Recent research has shown a strong correlation between gut dysbiosis and Alzheimer’s disease (AD). The purpose of this review is to investigate the relationship between gut dysbiosis, immune system activation, and the onset of AD and to examine current breakthroughs in microbiota-targeted AD therapeutics. A review of scientific literature was conducted to assess the correlation between gut dysbiosis and AD and the various factors associated. Gut dysbiosis produces an increase in harmful substances, such as bacterial amyloids, which makes the gut barrier and blood-brain barrier more permeable. This leads to the stimulation of immunological responses and an increase in cytokines such as interleukin-1β (IL-1β). As a result, gut dysbiosis accelerates the progression of AD. The review highlights the connection between gut dysbiosis and AD and the potential for microbiota-targeted therapies in AD treatment. Pictorial Abstract","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"13 1","pages":"305 - 315"},"PeriodicalIF":0.4000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Deep Insight into the Correlation Between Gut Dysbiosis and Alzheimer’s Amyloidopathy\",\"authors\":\"S. Kondaveeti, Dithu Thekkekkara, Lakshmi Narayanan T, S. Manjula, Y. M. Tausif, Amrita Babu, S. Meheronnisha\",\"doi\":\"10.1177/0976500X221150310\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recent research has shown a strong correlation between gut dysbiosis and Alzheimer’s disease (AD). The purpose of this review is to investigate the relationship between gut dysbiosis, immune system activation, and the onset of AD and to examine current breakthroughs in microbiota-targeted AD therapeutics. A review of scientific literature was conducted to assess the correlation between gut dysbiosis and AD and the various factors associated. Gut dysbiosis produces an increase in harmful substances, such as bacterial amyloids, which makes the gut barrier and blood-brain barrier more permeable. This leads to the stimulation of immunological responses and an increase in cytokines such as interleukin-1β (IL-1β). As a result, gut dysbiosis accelerates the progression of AD. The review highlights the connection between gut dysbiosis and AD and the potential for microbiota-targeted therapies in AD treatment. Pictorial Abstract\",\"PeriodicalId\":16761,\"journal\":{\"name\":\"Journal of Pharmacology & Pharmacotherapeutics\",\"volume\":\"13 1\",\"pages\":\"305 - 315\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacology & Pharmacotherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/0976500X221150310\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology & Pharmacotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0976500X221150310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

最近的研究表明,肠道生态失调与阿尔茨海默病(AD)之间存在着强烈的相关性。这篇综述的目的是研究肠道微生态失调、免疫系统激活和AD发病之间的关系,并考察微生物群靶向AD治疗的最新突破。对科学文献进行了综述,以评估肠道微生态失调与AD之间的相关性以及各种相关因素。肠道微生态失调会增加有害物质,如细菌淀粉样蛋白,使肠道屏障和血脑屏障更具渗透性。这导致免疫反应的刺激和细胞因子如白细胞介素-1β(IL-1β)的增加。因此,肠道生态失调加速了AD的进展。这篇综述强调了肠道生态失调与AD之间的联系,以及微生物群靶向治疗AD的潜力。图片摘要
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Deep Insight into the Correlation Between Gut Dysbiosis and Alzheimer’s Amyloidopathy
Recent research has shown a strong correlation between gut dysbiosis and Alzheimer’s disease (AD). The purpose of this review is to investigate the relationship between gut dysbiosis, immune system activation, and the onset of AD and to examine current breakthroughs in microbiota-targeted AD therapeutics. A review of scientific literature was conducted to assess the correlation between gut dysbiosis and AD and the various factors associated. Gut dysbiosis produces an increase in harmful substances, such as bacterial amyloids, which makes the gut barrier and blood-brain barrier more permeable. This leads to the stimulation of immunological responses and an increase in cytokines such as interleukin-1β (IL-1β). As a result, gut dysbiosis accelerates the progression of AD. The review highlights the connection between gut dysbiosis and AD and the potential for microbiota-targeted therapies in AD treatment. Pictorial Abstract
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
37
期刊最新文献
Allelic Variants in the Warfarin-related Genes VKORC1 and CYP2C9 in a Western Saudi Population N-Acetyl-l-Cysteine Ameliorations RenalFunction Early After Renal Ischemia and Reperfusion; it is not Protective over a LongTerm under a High-Sodium Diet in Rats Rationalization of Antibiotic Prescription: Modulation of the Gut Microbiome and Possibilities of Minimizing the Risks for the Development of Antibiotic Resistance—A Narrative Review The Science of Antioxidants: Balancing thePros and Cons for Our Health Use of Fixed-dose Combination Therapy with Remogliflozin and Vildagliptin as an Add-on Drug in Improving the Glycemic Control of Type 2 Diabetes Mellitus: An Observational Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1